OLUKEMI AINA: Open Payments
NPI 1124787650 · MELROSE PARK, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,328 in 81 payments from 10 companies in 2025. Trend: 2023 $775 · 2024 $1,637 · 2025 $1,328
Food & beverage: $1,328
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $466 |
| Janssen Pharmaceuticals, Inc | 12 | $246 |
| Alkermes, Inc. | 10 | $184 |
| Otsuka America Pharmaceutical, Inc. | 11 | $135 |
| Lundbeck LLC | 5 | $86 |
| E.R. Squibb & Sons, L.L.C. | 3 | $79 |
| Neurocrine BioSciences, Inc. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
Products named: VRAYLAR, INVEGA SUSTENNA, REXULTI, ARISTADA, COBENFY, INGREZZA, LYBALVI, CAPLYTA.
Industry payments across IL — which companies pay providers there.
